Safety
In Part 1 of the trial, any solicited local ARs within 7 days of mRNA-1010 vaccination were reported by 82.6%, 85.7%, and 91.3% of participants aged 18–49 years in the 50-µg, 100-µg, and 200-µg groups, respectively, and by 63.6%, 92.0%, and 90.5% of participants aged ≥50 years, respectively (Fig. 